Carolina D. Schinke

Hematology

4301 W Markham St
Little Rock, AR 72205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: August 07, 2026

Necrobiotic Xanthogranuloma Associated With IgG Kappa Smoldering Myeloma Presenting as Vision-Threatening Orbital Disease: Clinical Response to Plasma Cell-Directed Therapy.

Necrobiotic Xanthogranuloma Associated With IgG Kappa Smoldering Myeloma Presenting as Vision-Threatening Orbital Disease: Clinical Response to Plasma Cell-Directed Therapy.

Journal: Cureus

Published: June 19, 2026

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Journal: Cancers

Published: June 16, 2026

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

Journal: Future oncology (London, England)

Published: June 16, 2026

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: April 17, 2026

Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.

Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.

Journal: Blood advances

Published: April 14, 2026

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Journal: Transplantation and cellular therapy

Published: April 09, 2026

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study.

Journal: Blood

Published: February 25, 2026

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

Journal: HemaSphere

Published: January 09, 2026

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Journal: Blood cancer journal

Published: November 30, 2025

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Journal: Hematology/oncology and stem cell therapy

Published: November 15, 2025

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal?

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal?

Journal: American journal of hematology

Published: November 08, 2025

Showing 1-12 of 149

Last Updated: 09/26/2026